Signature Wealth Management Partners LLC Takes $261,000 Position in Eli Lilly and Company (NYSE:LLY)

Signature Wealth Management Partners LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 288 shares of the company’s stock, valued at approximately $261,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Everpar Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $1,845,000. International Assets Investment Management LLC lifted its stake in Eli Lilly and Company by 5.3% in the 4th quarter. International Assets Investment Management LLC now owns 12,597 shares of the company’s stock valued at $7,343,000 after buying an additional 632 shares in the last quarter. Kanawha Capital Management LLC lifted its stake in Eli Lilly and Company by 2.0% in the 4th quarter. Kanawha Capital Management LLC now owns 1,275 shares of the company’s stock valued at $743,000 after buying an additional 25 shares in the last quarter. Tennessee Valley Asset Management Partners purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth $181,000. Finally, Financial Council Asset Management Inc lifted its stake in shares of Eli Lilly and Company by 85.9% during the 4th quarter. Financial Council Asset Management Inc now owns 1,223 shares of the company’s stock worth $713,000 after purchasing an additional 565 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,214,704 shares of company stock worth $1,066,841,316. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of several research reports. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. Guggenheim lifted their price target on Eli Lilly and Company from $855.00 to $884.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Berenberg Bank raised their target price on shares of Eli Lilly and Company from $850.00 to $1,000.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Argus raised their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. Finally, Jefferies Financial Group lifted their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $945.35.

Eli Lilly and Company Stock Down 0.8 %

LLY traded down $7.30 during trading on Monday, hitting $884.38. 4,099,107 shares of the company’s stock were exchanged, compared to its average volume of 3,096,750. The business’s 50 day moving average is $872.13 and its two-hundred day moving average is $798.42. The stock has a market cap of $840.52 billion, a P/E ratio of 130.25, a PEG ratio of 1.81 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $966.10.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.59%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.